<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id>
<journal-title>Frontiers in Cellular Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-5102</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fncel.2024.1511314</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular Neuroscience</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: 15 years of frontiers in cellular neuroscience: blood brain barrier modulation and dysfunction in brain diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kempuraj</surname> <given-names>Duraisamy</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/391552/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Ceruti</surname> <given-names>Stefania</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/16518/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Institute for Neuro-Immune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University</institution>, <addr-line>Ft. Lauderdale, FL</addr-line>, <country>United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Pharmacological and Biomolecular Sciences &#x0201C;Rodolfo Paoletti&#x0201D;, Universit&#x000E0; degli Studi di Milano</institution>, <addr-line>Milan</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Hongjian Pu, University of Pittsburgh, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Matilde Balbi, The University of Queensland, Australia</p>
<p>Hansen Chen, Stanford University, United States</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Duraisamy Kempuraj <email>kduraisa&#x00040;nova.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>18</volume>
<elocation-id>1511314</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>10</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>10</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2024 Kempuraj and Ceruti.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Kempuraj and Ceruti</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/51767/15-years-of-frontiers-in-cellular-neuroscience-blood-brain-barrier-modulation-and-dysfunction-in-brain-diseases" ext-link-type="uri">Editorial on the Research Topic <article-title>15 years of frontiers in cellular neuroscience: blood brain barrier modulation and dysfunction in brain diseases</article-title></related-article>
<kwd-group>
<kwd>astrocytes</kwd>
<kwd>blood-brain barrier</kwd>
<kwd>endothelial cells</kwd>
<kwd>neurons</kwd>
<kwd>neurovascular unit</kwd>
<kwd>pericytes</kwd>
<kwd>tight junction proteins</kwd>
<kwd>neuroinflammatory disorders</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="16"/>
<page-count count="3"/>
<word-count count="1852"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Non-Neuronal Cells</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>The blood-brain barrier (BBB) is a dynamic structure that regulates transport (influx and efflux) of molecules between brain parenchyma and blood circulation and protects the brain from various pathogens, neurotoxic molecules from the periphery (Zapata-Acevedo et al., <xref ref-type="bibr" rid="B16">2024</xref>) and drugs (Ronaldson and Davis, <xref ref-type="bibr" rid="B13">2024</xref>). These protective actions are achieved due to the presence of tight junctions (TJ) with claudin 5, occluden, junctional adhesion molecules (JAMs), and zonula occludens-1 (ZO-1), adherens junctions (AJ) with Ve-Cadherin, catenin, and gap junctions (GJ) with connexins between adjacent endothelial cells that provide a physical barrier between brain parenchyma and peripheral blood (Kempuraj et al., <xref ref-type="bibr" rid="B9">2020</xref>; Andjelkovic et al., <xref ref-type="bibr" rid="B2">2023</xref>; Haruwaka et al., <xref ref-type="bibr" rid="B6">2019</xref>). Microvascular endothelial cells in the brain express many transporters that regulate the transport of molecules, including glucose. Neurovascular unit (NVU) consists of microvascular endothelial cells, astrocytes, pericytes (overall forming the BBB), and neurons. An intact BBB maintains homeostasis of the brain microenvironment for normal neuronal signaling, while disrupted BBB, derangement of TJ proteins associated with increased BBB permeability are observed in many neuroinflammatory and neurodegenerative disorders (Sweeney et al., <xref ref-type="bibr" rid="B14">2018</xref>; Kempuraj et al., <xref ref-type="bibr" rid="B9">2020</xref>). Neuroinflammation plays an important role in various brain disorders such as chronic neurodegenerative diseases including Alzheimer&#x00027;s disease, Parkinson&#x00027;s disease, Multiple Sclerosis (MS), stroke, and traumatic brain injury (TBI) (Zapata-Acevedo et al., <xref ref-type="bibr" rid="B16">2024</xref>). Systemic inflammatory disorders can cause and exacerbate neuroinflammatory responses in the brain (Paouri and Georgopoulos, <xref ref-type="bibr" rid="B12">2019</xref>; Cheng et al., <xref ref-type="bibr" rid="B4">2022</xref>). This Research Topic &#x0201C;<italic>Blood-brain barrier modulation and dysfunction in brain diseases</italic>&#x0201D; presents a collection of the following articles that demonstrate BBB disruption in the pathogenesis of brain disorders and how it can be therapeutically overcome.</p></sec>
<sec id="s2">
<title>Significance and articles in this Research Topic</title>
<p>Gemfibrozil is a lipid-lowering drug that showed neuroprotective effects by inhibiting glial cells, inflammation, oxidative stress and apoptosis in neurodegenerative diseases (Ivraghi et al., <xref ref-type="bibr" rid="B7">2024</xref>). A previous study has shown gemfibrozil&#x00027;s therapeutic beneficial effects in experimental autoimmune encephalomyelitis (EAE), an animal model of demyelinating disease MS (Dasgupta et al., <xref ref-type="bibr" rid="B5">2007</xref>). Gemfibrozil is known to suppress the expression of various inflammatory molecules in glial cells through its binding to peroxisome proliferator-activated receptor alpha (PPAR&#x003B1;). The paper by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2024.1375531">Mondal et al.</ext-link> for this Research Topic shows that gemfibrozil protects the integrity of the BBB/blood-spinal cord barrier (BSB), enhances Tregs, and decreases EAE pathogenesis through PPAR&#x003B2;, but not PPAR&#x003B1; in EAE mice. Further, the above study indicates an important immunomodulatory role of gemfibrozil and PPAR&#x003B2; that may be explored for therapeutic intervention in MS (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2024.1375531">Mondal et al.</ext-link>).</p>
<p>Pericytes are important for BBB integrity and microvascular blood flow in the brain and thus contribute to the pathophysiology of NVU (Bhowmick et al., <xref ref-type="bibr" rid="B3">2019</xref>). Pericytes are highly plastic and contractile cells that regulate blood flow in the brain microvessels, contribute to the maintenance of BBB integrity, angiogenesis, and control leukocyte transmigration (Alarcon-Martinez et al., <xref ref-type="bibr" rid="B1">2021</xref>). In their review article for this Research Topic, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2023.1267785">Fu et al.</ext-link> highlight pericyte biomarkers, their stem cell role and contractile and paracrine functions, and their role in neuroinflammation especially following ischemic stroke. Further, these authors suggest that brain pericytes could be therapeutic targets for many brain disorders such as neurodegenerative disorders, stroke, and TBI (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2023.1267785">Fu et al.</ext-link>). This review article provides significant and current information on the pathophysiology of pericytes that are fundamental but still partially unknown contributors to NVU/BBB functions (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2023.1267785">Fu et al.</ext-link>).</p>
<p>Oxidative stress causes neuronal damage in brain disorders including TBI. Inhibition of histone deacetylases (HDACs) has been shown to decrease the level of oxidative stress by reducing the expression of reactive oxygen species (Lu et al., <xref ref-type="bibr" rid="B10">2023</xref>). In the Research Topic paper, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2024.1368018">Inoue et al.</ext-link> studied the mechanism of how HDAC inhibition enhances BBB integrity using brain vascular endothelial cells. They report that incubation of immortalized human endothelial cells (HCMEC/D3) treated with W2A-16 (an HDAC inhibitor) retained the barrier property of endothelial cells as shown by increased trans-endothelial electrical resistance (TEER) and increased levels of BBB proteins as compared with untreated control cells. In this study, endothelial cells were cultured with hydrogen peroxidase and then the medium was switched to medium with or without W2A-16 and cultured. The above study concludes that HDAC inhibition by W2A-16 plays an important role in the formation of the BBB (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2024.1368018">Inoue et al.</ext-link>).</p>
<p>Microglia are brain-resident immune cells that present M0 (resting), M1 (proinflammatory), and M2 (anti-inflammatory) phenotypes (Wendimu and Hooks, <xref ref-type="bibr" rid="B15">2022</xref>). Microglial activation is implicated in neuroinflammation and neurodegenerative diseases. A recent article discussed microglia and BBB in health and diseases (Mayer and Fischer, <xref ref-type="bibr" rid="B11">2024</xref>). In a review article for this Research Topic, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2023.1117218">Deng et al.</ext-link> report crosstalk communication between the brain, heart, and spleen after stroke. These authors discuss how microglia-associated neuronal network inflammation induces cardiovascular disorders. Further, they indicate that these effects involve BBB disruption associated with increased permeability, entry of peripheral immune cells into the brain and entry of brain-derived molecules into the peripheral circulation and peripheral organs and activation of monocytes (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2023.1117218">Deng et al.</ext-link>).</p>
<p>Detection of neuroinflammatory biomarkers in cerebrospinal fluid (CSF), blood, and brain tissues, and their validation in <italic>in vitro</italic> cell culture disease models are useful for diagnoses and for assessing the severity of neuroinflammatory and neurodegenerative disorders especially associated with NVU/BBB components (Kadry et al., <xref ref-type="bibr" rid="B8">2020</xref>). The review article by <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2024.1491952">Kempuraj et al.</ext-link> on this Research Topic provides an overview of the most important markers for NVU/BBB, neuroinflammatory and neurodegenerative disorders expressed by various brain cells (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2024.1491952">Kempuraj et al.</ext-link>). These authors indicate that derangements and damage to the TJ, AJ, and GJ components of the BBB lead to increased BBB permeability, resulting in edema, increased neuroinflammation and neuronal damage in various brain disorders (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fncel.2024.1491952">Kempuraj et al.</ext-link>). Additionally, this review article highlights that BBB-on-a-chip modeling offers promising potential for the pre-clinical in-depth understanding of NVU/BBB brain pathologies and neurotherapeutics.</p></sec>
<sec id="s3">
<title>Concluding remarks</title>
<p>Neuroinflammatory and neurodegenerative disorders show NVU/BBB dysfunctions and increased BBB permeability. Understanding the mechanisms underlying these pathological events is important for the assessment of disease severity and to identify innovative treatment options for brain disorders. This Research Topic provides several insights on the NVU/BBB which could lead to the development of more effective therapeutic options for these disorders.</p></sec>
</body>
<back>
<sec sec-type="author-contributions" id="s4">
<title>Author contributions</title>
<p>DK: Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Resources, Conceptualization. SC: Writing &#x02013; review &#x00026; editing.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were editorial board members of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="disclaimer" id="s5">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alarcon-Martinez</surname> <given-names>L.</given-names></name> <name><surname>Yemisci</surname> <given-names>M.</given-names></name> <name><surname>Dalkara</surname> <given-names>T.</given-names></name></person-group> (<year>2021</year>). <article-title>Pericyte morphology and function</article-title>. <source>Histol. Histopathol.</source> <volume>36</volume>, <fpage>633</fpage>&#x02013;<lpage>643</lpage>. <pub-id pub-id-type="doi">10.14670/HH-18-314</pub-id><pub-id pub-id-type="pmid">33595091</pub-id></citation></ref>
<ref id="B2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andjelkovic</surname> <given-names>A. V.</given-names></name> <name><surname>Situ</surname> <given-names>M.</given-names></name> <name><surname>Citalan-Madrid</surname> <given-names>A. F.</given-names></name> <name><surname>Stamatovic</surname> <given-names>S. M.</given-names></name> <name><surname>Xiang</surname> <given-names>J.</given-names></name> <name><surname>Keep</surname> <given-names>R. F.</given-names></name></person-group> (<year>2023</year>). <article-title>Blood-brain barrier dysfunction in normal aging and neurodegeneration: mechanisms, impact, and treatments</article-title>. <source>Stroke</source> <volume>54</volume>, <fpage>661</fpage>&#x02013;<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.122.040578</pub-id><pub-id pub-id-type="pmid">36848419</pub-id></citation></ref>
<ref id="B3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhowmick</surname> <given-names>S.</given-names></name> <name><surname>D&#x00027;Mello</surname> <given-names>V.</given-names></name> <name><surname>Caruso</surname> <given-names>D.</given-names></name> <name><surname>Wallerstein</surname> <given-names>A.</given-names></name> <name><surname>Abdul-Muneer</surname> <given-names>P. M.</given-names></name></person-group> (<year>2019</year>). <article-title>Impairment of pericyte-endothelium crosstalk leads to blood-brain barrier dysfunction following traumatic brain injury</article-title>. <source>Exp. Neurol.</source> <volume>317</volume>, <fpage>260</fpage>&#x02013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2019.03.014</pub-id><pub-id pub-id-type="pmid">30926390</pub-id></citation></ref>
<ref id="B4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>W.</given-names></name> <name><surname>Zhao</surname> <given-names>Q.</given-names></name> <name><surname>Li</surname> <given-names>C.</given-names></name> <name><surname>Xu</surname> <given-names>Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Neuroinflammation and brain-peripheral interaction in ischemic stroke: a narrative review</article-title>. <source>Front. Immunol.</source> <volume>13</volume>:<fpage>1080737</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.1080737</pub-id><pub-id pub-id-type="pmid">36685518</pub-id></citation></ref>
<ref id="B5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname> <given-names>S.</given-names></name> <name><surname>Roy</surname> <given-names>A.</given-names></name> <name><surname>Jana</surname> <given-names>M.</given-names></name> <name><surname>Hartley</surname> <given-names>D. M.</given-names></name> <name><surname>Pahan</surname> <given-names>K.</given-names></name></person-group> (<year>2007</year>). <article-title>Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha</article-title>. <source>Mol. Pharmacol.</source> <volume>72</volume>, <fpage>934</fpage>&#x02013;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1124/mol.106.033787</pub-id><pub-id pub-id-type="pmid">17625103</pub-id></citation></ref>
<ref id="B6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haruwaka</surname> <given-names>K.</given-names></name> <name><surname>Ikegami</surname> <given-names>A.</given-names></name> <name><surname>Tachibana</surname> <given-names>Y.</given-names></name> <name><surname>Ohno</surname> <given-names>N.</given-names></name> <name><surname>Konishi</surname> <given-names>H.</given-names></name> <name><surname>Hashimoto</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Dual microglia effects on blood brain barrier permeability induced by systemic inflammation</article-title>. <source>Nat. Commun.</source> <volume>10</volume>:<fpage>5816</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-019-13812-z</pub-id><pub-id pub-id-type="pmid">31862977</pub-id></citation></ref>
<ref id="B7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ivraghi</surname> <given-names>M. S.</given-names></name> <name><surname>Zamanian</surname> <given-names>M. Y.</given-names></name> <name><surname>Gupta</surname> <given-names>R.</given-names></name> <name><surname>Achmad</surname> <given-names>H.</given-names></name> <name><surname>Alsaab</surname> <given-names>H. O.</given-names></name> <name><surname>Hjazi</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Neuroprotective effects of gemfibrozil in neurological disorders: focus on inflammation and molecular mechanisms</article-title>. <source>CNS Neurosci. Ther.</source> <volume>30</volume>:<fpage>e14473</fpage>. <pub-id pub-id-type="doi">10.1111/cns.14473</pub-id><pub-id pub-id-type="pmid">37904726</pub-id></citation></ref>
<ref id="B8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kadry</surname> <given-names>H.</given-names></name> <name><surname>Noorani</surname> <given-names>B.</given-names></name> <name><surname>Cucullo</surname> <given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity</article-title>. <source>Fluids Barriers CNS.</source> <volume>17</volume>:<fpage>69</fpage>. <pub-id pub-id-type="doi">10.1186/s12987-020-00230-3</pub-id><pub-id pub-id-type="pmid">33208141</pub-id></citation></ref>
<ref id="B9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kempuraj</surname> <given-names>D.</given-names></name> <name><surname>Ahmed</surname> <given-names>M. E.</given-names></name> <name><surname>Selvakumar</surname> <given-names>G. P.</given-names></name> <name><surname>Thangavel</surname> <given-names>R.</given-names></name> <name><surname>Dhaliwal</surname> <given-names>A. S.</given-names></name> <name><surname>Dubova</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Brain injury-mediated neuroinflammatory response and Alzheimer&#x00027;s disease</article-title>. <source>Neuroscientist</source> <volume>26</volume>, <fpage>134</fpage>&#x02013;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1177/1073858419848293</pub-id><pub-id pub-id-type="pmid">31092147</pub-id></citation></ref>
<ref id="B10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>Y.</given-names></name> <name><surname>Xu</surname> <given-names>S.</given-names></name> <name><surname>Wei</surname> <given-names>L.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>W.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>HDAC inhibitor attenuates rat traumatic brain injury induced neurological impairments</article-title>. <source>Heliyon</source> <volume>9</volume>:<fpage>e18485</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e18485</pub-id><pub-id pub-id-type="pmid">37560709</pub-id></citation></ref>
<ref id="B11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname> <given-names>M. G.</given-names></name> <name><surname>Fischer</surname> <given-names>T.</given-names></name></person-group> (<year>2024</year>). <article-title>Microglia at the blood brain barrier in health and disease</article-title>. <source>Front. Cell. Neurosci.</source> <volume>18</volume>:<fpage>1360195</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2024.1360195</pub-id><pub-id pub-id-type="pmid">38550920</pub-id></citation></ref>
<ref id="B12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paouri</surname> <given-names>E.</given-names></name> <name><surname>Georgopoulos</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Systemic and CNS inflammation crosstalk: implications for Alzheimer&#x00027;s disease</article-title>. <source>Curr. Alzheimer Res.</source> <volume>16</volume>, <fpage>559</fpage>&#x02013;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.2174/1567205016666190321154618</pub-id><pub-id pub-id-type="pmid">30907316</pub-id></citation></ref>
<ref id="B13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ronaldson</surname> <given-names>P. T.</given-names></name> <name><surname>Davis</surname> <given-names>T. P.</given-names></name></person-group> (<year>2024</year>). <article-title>Blood-brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics</article-title>. <source>Expert Opin. Drug Deliv.</source> <volume>21</volume>, <fpage>71</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1080/17425247.2024.2306138</pub-id><pub-id pub-id-type="pmid">38217410</pub-id></citation></ref>
<ref id="B14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname> <given-names>M. D.</given-names></name> <name><surname>Sagare</surname> <given-names>A. P.</given-names></name> <name><surname>Zlokovic</surname> <given-names>B. V.</given-names></name></person-group> (<year>2018</year>). <article-title>Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders</article-title>. <source>Nat. Rev. Neurol.</source> <volume>14</volume>, <fpage>133</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2017.188</pub-id><pub-id pub-id-type="pmid">29377008</pub-id></citation></ref>
<ref id="B15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wendimu</surname> <given-names>M. Y.</given-names></name> <name><surname>Hooks</surname> <given-names>S. B.</given-names></name></person-group> (<year>2022</year>). <article-title>Microglia Phenotypes in Aging and Neurodegenerative Diseases</article-title>. <source>Cells.</source> <volume>11</volume>:<fpage>2091</fpage>. <pub-id pub-id-type="doi">10.3390/cells11132091</pub-id><pub-id pub-id-type="pmid">35805174</pub-id></citation></ref>
<ref id="B16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zapata-Acevedo</surname> <given-names>J. F.</given-names></name> <name><surname>Mantilla-Galindo</surname> <given-names>A.</given-names></name> <name><surname>Vargas-Sanchez</surname> <given-names>K.</given-names></name> <name><surname>Gonzalez-Reyes</surname> <given-names>R. E.</given-names></name></person-group> (<year>2024</year>). <article-title>Blood-brain barrier biomarkers</article-title>. <source>Adv. Clin. Chem.</source> <volume>121</volume>, <fpage>1</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/bs.acc.2024.04.004</pub-id><pub-id pub-id-type="pmid">38797540</pub-id></citation></ref>
</ref-list>
</back>
</article>